北京利德曼生化股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025-036 2025 年 08 月 1 北京利德曼生化股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人尧子、主管会计工作负责人欧阳旭及会计机构负责人(会计主 管人员)欧阳旭声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 北京利德曼生化股份有限公司 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公 司对任何投资者及相关人士的承诺；投资者及相关人士均应对此保持足够的 风险认识，并且应当理解计划、预测与承诺之间的差异。 公司可能面临的风险详见本报告"第三节管理层讨论与分析"之"十、公司 面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公 ...

天眼查商业履历信息显示，北京利德曼生化股份有限公司，成立于1997年，位于北京市，是一家以从事 医药制造业为主的企业。企业注册资本42380.5235万人民币，实缴资本42380.5235万人民币。公司法定 代表人为尧子。 通过天眼查大数据分析，北京利德曼生化股份有限公司共对外投资了14家企业，参与招投标项目273 次，知识产权方面有商标信息18条，专利信息130条，此外企业还拥有行政许可172个。 来源：金融界 金融界消息 截至2025年8月25日收盘，利德曼（300289）报收于9.08元，下跌1.3%，换手率6.99%，成 交量37.97万手，成交金额3.48亿元。 资金流向方面，今日主力资金净流出4213.91万元，占比成交额12.11%。其中，超大单净流出1327.59万 元、占成交额3.81%，大单净流出2886.32万元、占成交额8.29%，中单净流出流入833.60万元、占成交 额2.39%，小单净流入3380.31万元、占成交额9.71%。 利德曼最新一期业绩显示，截至2025一季报，公司营业总收入7890.87万元、同比减少16.61%，归属净 利润125.17万元，同比增长53.73%， ...

Group 1 - The stock price of Lidman closed at 9.72 yuan on August 19, 2025, down 3.95% from the previous trading day [1] - The opening price for the day was 9.90 yuan, with an intraday high of 10.37 yuan and a low of 9.70 yuan, resulting in a volatility of 6.62% [1] - The total trading volume for the day was 692,433 hands, with a transaction amount of 6.91 billion yuan [1] Group 2 - Lidman's main business includes the research, production, and sales of in vitro diagnostic reagents and instruments, covering areas such as biochemical diagnosis and immunodiagnosis [1] - The company operates in sectors including medical devices, assisted reproduction, and precision medicine [1] Group 3 - On the morning of August 19, Lidman experienced a quick rebound, reaching a price of 10.24 yuan at 9:37 AM, with a rise of over 2% within 5 minutes [1] - The net outflow of main funds for the day was 49.21 million yuan, with a cumulative net outflow of 203 million yuan over the past five trading days [1]

Core Points - The latest stock price of Lidman is 10.12 yuan as of August 18, 2025, showing an increase of 0.20 yuan from the previous trading day [1] - The opening price for the day was 9.92 yuan, with a highest price of 10.54 yuan and a lowest price of 9.82 yuan [1] - The trading volume reached 775,606 hands, with a total transaction amount of 7.82 billion yuan [1] Company Overview - Lidman's main business includes the research, development, production, and sales of in vitro diagnostic reagents and instruments, covering areas such as biochemical diagnosis and immunodiagnosis [1] - The company operates within the medical device sector [1] Market Activity - On the morning of August 18, Lidman experienced a rapid pullback, with the stock price reported at 10.15 yuan at 9:42 AM, showing a decline of over 2% within five minutes [1] - The net outflow of main funds for the day was 63.74 million yuan, with a cumulative net outflow of 135 million yuan over the past five trading days [1]

金融界消息 截至2025年8月15日收盘，利德曼（300289）报收于9.92元，下跌1.39%，换手率13.04%， 成交量70.81万手，成交金额6.87亿元。 来源：金融界 天眼查商业履历信息显示，北京利德曼生化股份有限公司，成立于1997年，位于北京市，是一家以从事 医药制造业为主的企业。企业注册资本42380.5235万人民币，实缴资本42380.5235万人民币。公司法定 代表人为尧子。 通过天眼查大数据分析，北京利德曼生化股份有限公司共对外投资了14家企业，参与招投标项目271 次，知识产权方面有商标信息18条，专利信息130条，此外企业还拥有行政许可178个。 资金流向方面，今日主力资金净流出1056.22万元，占比成交额1.54%。其中，超大单净流入401.59万 元、占成交额0.58%，大单净流出1457.81万元、占成交额2.12%，中单净流出流出129.69万元、占成交 额0.19%，小单净流入1185.91万元、占成交额1.73%。 利德曼最新一期业绩显示，截至2025一季报，公司营业总收入7890.87万元、同比减少16.61%，归属净 利润125.17万元，同比增长53.73%， ...

证券之星消息，8月14日医疗器械板块较上一交易日下跌2.16%，利德曼领跌。当日上证指数报收于 3666.44，下跌0.46%。深证成指报收于11451.43，下跌0.87%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300289 | 利德曼 | 10.06 | -11.21% | 106.05万 | | 10.85 Z | | 300981 | 中红医疗 | 16.00 | -9.91% | 26.13万 | | 4.31亿 | | 688677 | 海泰新光 | 45.30 | -7.93% | 4.91万 | | 2.28亿 | | 301235 | や康浩浄 | 29.72 | -7.90% | 15.14万 | | 4.42亿 | | 832278 | 鹿得医疗 | 11.23 | -7.88% | 9.33万 | | 1.07亿 | | 688212 | 澳华内镜 | 49.14 | -7.79% | 4.70万 | | 2.34亿 ...

Group 1 - The medical device sector experienced a short-term decline, with Lide Man falling over 9% [1] - Other companies such as Zhonghong Medical, Dabo Medical, Aohua Endoscopy, and Shangrong Medical also saw declines [1]

利德曼最新一期业绩显示，截至2025一季报，公司营业总收入7890.87万元、同比减少16.61%，归属净 利润125.17万元，同比增长53.73%，扣非净利润329.55万元，同比增长32.46%，流动比率15.640、速动 比率14.392、资产负债率5.13%。 天眼查商业履历信息显示，北京利德曼生化股份有限公司，成立于1997年，位于北京市，是一家以从事 医药制造业为主的企业。企业注册资本42380.5235万人民币，实缴资本42380.5235万人民币。公司法定 代表人为尧子。 金融界消息 截至2025年8月13日收盘，利德曼（300289）报收于11.33元，上涨4.91%，换手率22.61%， 成交量122.81万手，成交金额13.85亿元。 资金流向方面，今日主力资金净流入6644.74万元，占比成交额4.8%。其中，超大单净流入1595.43万 元、占成交额1.15%，大单净流入5049.32万元、占成交额3.65%，中单净流出流出3921.53万元、占成交 额2.83%，小单净流出2723.21万元、占成交额1.97%。 通过天眼查大数据分析，北京利德曼生化股份有限公司共对外投资了14家 ...

Group 1 - The core point of the news is that Lidman Biochemical Co., Ltd. has seen a stock price increase of 5.46%, reaching 11.39 CNY per share, with a total market capitalization of 6.196 billion CNY [1] - The company is located in Beijing Economic and Technological Development Zone and focuses on the research and production of biochemical reagents, operating 10 subsidiaries and a nationwide distribution network [1] - Lidman has a daily production capacity of 4000 liters and aims to advance biological sciences and improve the quality of life for people [1] Group 2 - As of July 31, the number of shareholders for Lidman is 17,000, with an average of 31,900 circulating shares per person [2] - For the first quarter of 2025, Lidman reported operating revenue of 78.9087 million CNY, a year-on-year decrease of 16.61%, while the net profit attributable to shareholders was -1.2517 million CNY, reflecting a year-on-year increase of 53.73% [2]

Core Viewpoint - Lidman Biochemical Co., Ltd. has shown a significant stock price increase and is actively engaged in the development and production of biochemical reagents, aiming to enhance the quality of life and advance biological sciences [1][2]. Group 1: Stock Performance - On August 12, Lidman’s stock rose by 5.47%, reaching a price of 11.18 yuan per share, with a trading volume of 2.11 billion yuan and a turnover rate of 3.59%, resulting in a total market capitalization of 60.82 billion yuan [1]. Group 2: Company Overview - Lidman is located in Beijing Economic and Technological Development Zone and operates 10 subsidiaries along with a nationwide distribution network, achieving a daily production capacity of 4000 liters [1]. - The company is committed to promoting advancements in biological sciences and improving the quality of life for people, having established a business organization across the country to better understand market trends and meet customer needs [1]. Group 3: Financial Performance - As of July 31, Lidman had 17,000 shareholders, with an average of 31,900 circulating shares per person [2]. - For the first quarter of 2025, Lidman reported operating revenue of 78.91 million yuan, a year-on-year decrease of 16.61%, while the net profit attributable to shareholders was -1.25 million yuan, reflecting a year-on-year increase of 53.73% [2].